Maria Sundvall
MD PhD; Specialist Physician in Clinical Oncology
mahesu@utu.fi Kiinamyllynkatu 10 Turku |
Asiantuntijuusalueet
clinical oncology; breast and prostate cancer; targeted cancer therapeutics; cancer biology; cell signaling; posttranslational modifications; dna repair pathways
clinical oncology; breast and prostate cancer; targeted cancer therapeutics; cancer biology; cell signaling; posttranslational modifications; dna repair pathways
Biografia
Maria Sundvall received her MD degree from the University of Turku in 2003, and defended her PhD thesis at the Department of Medical Biochemistry and Genetics, University of Turku, in 2007. From 2011 she worked nearly 4 years as a postdoctoral fellow in the laboratory of Prof. Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. After returning to Finland in 2015 she established her own research group at the University of Turku. Dr. Sundvall received a specialist physician degree in clinical oncology in 2018. Since 2018 Dr. Sundvall has worked as a part-time clinical lecturer at the Institute of Biomedicine, a part-time Academy of Finland clinical researcher and a part-time specialist physician in clinical oncology at Turku University Hospital.
Maria Sundvall received her MD degree from the University of Turku in 2003, and defended her PhD thesis at the Department of Medical Biochemistry and Genetics, University of Turku, in 2007. From 2011 she worked nearly 4 years as a postdoctoral fellow in the laboratory of Prof. Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. After returning to Finland in 2015 she established her own research group at the University of Turku. Dr. Sundvall received a specialist physician degree in clinical oncology in 2018. Since 2018 Dr. Sundvall has worked as a part-time clinical lecturer at the Institute of Biomedicine, a part-time Academy of Finland clinical researcher and a part-time specialist physician in clinical oncology at Turku University Hospital.
Tutkimus
Dr. Sundvall has 20 years of experience in studying molecular mechanisms of cancer. Currently she is a principal investigator at University of Turku, and her group is focusing on investigating the role fo DNA repair pathways in prostate cancer. Links:
https://www.utu.fi/en/university/faculty-of-medicine/institute-of-biomedicine/research/cancer-research
Opetus
Dr. Sundvall has several years of experience in teaching medical students as a clinical lecturer and a university teacher in the fields of medical biochemistry, molecular medicine and cancer during the last 15 years.
Dr. Sundvall has several years of experience in teaching medical students as a clinical lecturer and a university teacher in the fields of medical biochemistry, molecular medicine and cancer during the last 15 years.
Julkaisut 
2/5
- Glucocorticoid receptor-induced non-muscle caldesmon regulates metastasis in castration-resistant prostate cancer (2023)
- Oncogenesis
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study (2023)
- Cancer Medicine
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - TSPO is a potential independent prognostic factor associated with cellular respiration and p16 in head and neck squamous cell carcinoma (2023)
- Frontiers in Oncology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Ex vivo -mallit ja nestebiopsia yksilöllistetyssä syövänhoidossa (2021)
- Duodecim
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Geeniohjatun syövän hoidon työryhmä hoitopäätösten apuna : Läntisen syöpäkeskuksen kokemus (2021)
- Duodecim
(D1 Artikkeli ammattilehdessä) - More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond (2021)
- Cancers
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Therapeutic Potential of Targeting the SUMO Pathway in Cancer (2021)
- Cancers
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Role of Ubiquitin and SUMO in Intracellular Trafficking (2020)
- Current Issues in Molecular Biology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Uusia työkaluja paikallisesti edenneen ja etäpesäkkeisen eturauhassyövän lääkehoitoon (2020)
- Duodecim
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - PARP Inhibitors in Prostate Cancer-the Preclinical Rationale and Current Clinical Development (2019)
- Genes
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä)
Turun yliopiston Tutkimustietojärjestelmän portaali